**Core Concept:** Acute Myeloid Leukemia M3 (AML-M3) is a subtype of acute myeloid leukemia (AML) characterized by a specific chromosomal translocation. Chromosomal translocation is a genetic abnormality where two non-adjacent chromosomes or chromosome segments exchange their genetic material, leading to the production of abnormal proteins and disruption of normal cellular processes.

**Why the Correct Answer is Right:** In the case of AML-M3, the chromosomal translocation involves chromosomes 15 and 17. This translocation results in the fusion of two genes: RUNX1 (also known as CBFB) on chromosome 15 and RUNX1T1 (ETO) on chromosome 17. This fusion protein disrupts normal hematopoiesis (bone marrow cell production) and leads to the development of AML-M3.

**Why Each Wrong Option is Incorrect:**

A. This option is incorrect because it does not mention the specific chromosomal translocation associated with AML-M3.
B. This option is incorrect because it does not address the chromosomal translocation involving chromosomes 15 and 17, which is the key genetic abnormality in AML-M3.
C. This option is incorrect because it does not mention the specific fusion gene (RUNX1-RUNX1T1) resulting from the chromosomal translocation in AML-M3.
D. This option is incorrect because it does not address the disruption of normal hematopoiesis caused by the fusion protein in AML-M3.

**Clinical Pearl:** The understanding of chromosomal translocations, like in AML-M3, is crucial in the diagnosis of specific types of leukemia and in guiding appropriate treatment strategies. Knowledge of the specific genetic abnormality helps healthcare professionals tailor treatments, such as targeted therapies, to address the underlying cause of the disease, improving patient outcomes.